Negative regulation of the deacetylase SIRT1 by DBC1

Nature

Volumn 451, Issue 7178, 2008, Pages 587-590

  Zhao, Wenhui ^a   Kruse, Jan Philipp ^a   Tang, Yi ^a   Jung, Sung Yun ^b   Qin, Jun ^b   Gu, Wei ^a  

^a Department of Pathology College of Physicians and Surgeons Columbia University ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELETED IN BREAST CANCER 1 PROTEIN; HYDROLASE INHIBITOR; PROTEIN P53; SIRTUIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITION; INHIBITOR; METABOLISM; RNA; TUMOR;

ACETYLATION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEACETYLATION; ENZYME INHIBITION; ENZYME REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; RNA INTERFERENCE; UPREGULATION;

MUS;

EID: 38749132992     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06515     Document Type: Article

References (30)

1. Bordone, L. & Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nature Rev. Mol. Cell Biol. 6, 298-305 (2005).
2. North, B. J. & Verdin, E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 5, 224.1-224.12 (2004).
3. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 5, 493-506 (2006).
4. Luo, J. et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107, 137-148 (2001).
5. Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383-2396 (2002).
6. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159 (2001).
7. Motta, M. C. et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551-563 (2004).
8. Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015 (2004).
9. Kitamura, Y. I. et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2, 153-163 (2005).
10. Cheng, H. L. et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl Acad. Sci. USA 100, 10794-10799 (2003).
11. Chen, W. Y. et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123, 437-448 (2005).
12. Yeung, F. et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23, 2369-2380 (2004).
13. Greene, W. C. & Chen, L. F. Regulation of NF-kappaB action by reversible acetylation. Novartis Found. Symp. 259, 208-217; discussion 218-225 (2004).
14. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434, 113-118 (2005).
15. Cohen, H. Y. et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627-638 (2004).
16. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
17. Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377-381 (2000).
18. Hamaguchi, M. et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc. Natl Acad. Sci. USA 99, 13647-13652 (2002).
19. Sundararajan, R., Chen, G., Mukherjee, C. & White, E. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene 24, 4908-4920 (2005).
20. North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M. & Verdin, E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 11, 437-444 (2003).
21. Knowles, M. A., Aveyard, J. S., Taylor, C. F., Harnden, P. & Bass, S. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett. 225, 121-130 (2005).
22. Heltweg, B. et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66, 4368-4377 (2006).
23. Olaharski, A. J. et al. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet 1, e77 (2005).
24. Mai, A. et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48, 7789-7795 (2005).
25. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122 (2006).
26. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006).
27. Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003).
28. Kaeberlein, M. et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045 (2005).
29. Borra, M. T., Smith, B. C. & Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195 (2005).
30. Viswanathan, M., Kim, S. K., Berdichevsky, A. & Guarente, L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 9, 605-615 (2005).